Shots: The P-III PANORAMA trial involves assessing of Eylea (q8w, q16w) vs PBO (sham injection) in 402 patients with moderately-severe and severe NPDR for 52 weeks P-III PANORAMA trial results: […]readmore
Tags : Regeneron
Shots: The two P-III study involves assessing of Dupixent + SOC vs PBO (nasal spray alone) in adults with CRSwNP & Dupixent + mometasone furoate nasal spray (MFNS) vs MFNS […]readmore
Shots: Regeneron is presenting results from studies evaluating Libtayo in indications NSCLC (P-I), CSCC(P-I), HCC(P-I), BCC (P-II), R/M Cervical Cancer (P-I), Libtayo + RT+ GM-CSF for R/M HNSCC (P-I) Libtayo […]readmore
Shots: The sBLA involves results of P-III PANORAMA trial assessing EYLEA treatment from moderate severe-to-severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME) The announced PDUFA date for EYLEA […]readmore
Shots: Results of P-III ODYSSEY OUTCOMES assessing PRALUENT(alirocumab) IV (N= 18,924), having an acute coronary syndrome (ACS), such as a heart attack, b/w 1-12 mos before being enrolled The US […]readmore
Shots: Collaboration is focused on using Regeneron’s Velocisuite platform for the discovery and characterization of human antibodies, T cell receptors and bluebird will contribute in gene transfer and cell therapy […]readmore